Rilvegostomig(Rilvegostomig) - 药物靶点：PD-1 x TIGIT_在研适应症：食管腺癌，Claudin 18.2阳性 / HER2阴性的实体瘤，CLDN18.2阳性胃食管交界处腺癌_专利_临床

概要

基本信息

药物类型

双特异性抗体

别名

AZD 2936、AZD-2936

靶点

PD-1 x TIGIT

作用方式

抑制剂

作用机制

PD-1抑制剂(细胞程序性死亡-1抑制剂)、TIGIT抑制剂(T细胞免疫球蛋白ITIM结构域抑制剂)

治疗领域

肿瘤消化系统疾病呼吸系统疾病+ [3]

在研适应症

食管腺癌Claudin 18.2阳性 / HER2阴性的实体瘤CLDN18.2阳性胃食管交界处腺癌+ [39]

非在研适应症-

原研机构

AstraZeneca PLC

在研机构

AstraZeneca PLCAstraZeneca AB

Compugen Ltd.

+ [3]

非在研机构-

权益机构

AstraZeneca PLC

MedImmune LLC

Compugen Ltd.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 18899517L

来源: *****

Sequence Code 18899526H

来源: *****

Sequence Code 719888445H

来源: *****

Sequence Code 719888446L

来源: *****

关联

34

项与 Rilvegostomig 相关的临床试验

NCT07431281

/ Recruiting临床3期

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

开始日期2026-02-03

申办/合作机构

AstraZeneca PLC

NCT07221253

/ Recruiting临床3期

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)

The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

开始日期2025-12-04

申办/合作机构

AstraZeneca PLC

NCT07161414

/ Recruiting临床1期

A Phase I, Multicenter, Dose Finding and Dose Confirmation Study to Investigate the Pharmacokinetics, and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ARTEMIDE-subQ)

The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with standard of care therapy for whom immunooncology (IO) monotherapy would be deemed appropriate by the investigator.

开始日期2025-11-25

申办/合作机构

AstraZeneca PLC

[+1]

100 项与 Rilvegostomig 相关的临床结果

登录后查看更多信息

100 项与 Rilvegostomig 相关的转化医学

登录后查看更多信息

100 项与 Rilvegostomig 相关的专利（医药）

登录后查看更多信息

5

项与 Rilvegostomig 相关的文献（医药）

2026-01-01·JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer

Article

作者: Lim, Eric ; Forcina, Alessandra ; Opitz, Isabelle ; Yanagawa, Jane ; Batig, Anastasiya ; Harpole, David ; Felip, Enriqueta ; Tsutani, Yasuhiro ; Jones, David R ; Lyfar, Pavlo ; Bodla, Shankar ; Dacic, Sanja ; Ganti, Apar Kishor ; Tan, Daniel S W

BACKGROUND:

Five-year disease recurrence rates for patients with stage I non-small cell lung cancer (NSCLC) postsurgery are variable (15%-40%). There is an urgent need for novel biomarker strategies to identify high-risk patients who may benefit from adjuvant treatment. High-risk pathologic features, including high-grade histology and lymphovascular or visceral pleural invasion, serve as independent risk factors for worse outcomes. Preoperative circulating tumor DNA (ctDNA) detection is also correlated with poorer outcomes in stage I NSCLC. Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate composed of a humanized anti-TROP2 antibody conjugated to a potent topoisomerase I inhibitor via a plasma-stable linker, and rilvegostomig, an Fc-reduced monovalent bispecific humanized IgG1 antibody targeting both PD-1 and TIGIT receptors, have shown promise in NSCLC studies. Combining Dato-DXd with rilvegostomig may improve treatment outcomes in selected patients with stage I NSCLC.

METHODS:

TROPION-Lung12 (NCT06564844) is a phase 3 randomized study enrolling approximately 660 patients with stage I adenocarcinoma without actionable genomic alterations who have undergone complete surgical resection. Eligible patients must have preoperative ctDNA-positive status or 1 or more high-risk pathologic features. Patients will be randomized 2:1:2 to receive Dato-DXd (6 mg/kg intravenously [IV] every 3 weeks) plus rilvegostomig (750 mg IV every 3 weeks) for 4 cycles, followed by rilvegostomig (up to 12 months/18 cycles total), rilvegostomig alone (up to 12 months/18 cycles total), or standard of care (SoC) for up to 12 months. The primary endpoint is disease-free survival, assessed using blinded independent central review according to RECIST v1.1, with key secondary endpoints including overall survival, for the Dato-DXd plus rilvegostomig arm versus the SoC arm.

POSTGRADUATE MEDICAL JOURNAL

Retraction of: Volrustomig/Rilvegostomig related “triple M”—myasthenia gravis and overlap syndrome

Article

Frontiers in Oncology

Correction: TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations

[This corrects the article DOI: 10.3389/fonc.2025.1721624.].

295

项与 Rilvegostomig 相关的新闻（医药）

2026-05-12

·PRNewswire

Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

HOLON, Israel, May 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 Stifel Virtual Targeted Oncology Forum. The presentation will take place on Tuesday, May 19, 2026, at 10:00-10:25 AM ET. A live webcast will be accessible on the Investor Relations section of the Compugen website at . A replay will also be available following the live event. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, and COM902, an anti-TIGIT antibody, have been evaluated for the treatment of solid tumors as monotherapy and in combinations. Currently, Compugen is conducting a blinded randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen's has an early-stage immuno-oncology pipeline consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company contact: Investor relations Email: [email protected] Tel: +1 (628) 241-0071 SOURCE Compugen Ltd. 21% more press release views with Request a Demo

免疫疗法临床1期引进/卖出临床2期临床3期

2026-05-11

·药事纵横

突围癌症之王

近日，FDA批准RMC-6236(Daraxonrasib)在其扩大使用计划下投入使用(EAP)，用于KRAS突变胰腺癌的治疗。该计划又称"同情用药"机制，允许病情严重或处于终末期的患者在临床试验之外接受研究性疗法，即在药物正式获批前，患者可通过主治医生申请获得药物的使用。FDA这一绿灯反映出胰腺癌存在巨大未被满足的临床需求，Daraxonrasib有望给胰腺癌患者带来希望之光。（一）癌症之王胰腺癌胰腺癌是一种起源于胰腺导管上皮及腺泡细胞的恶性肿瘤。绝大多数胰腺癌开始于胰腺中的外分泌细胞的生长失控，胰腺的外分泌恶性肿瘤主要是来源于胰腺导管上皮的腺癌,大约占到胰腺癌的90%以上。胰腺癌恶性程度高，因胰腺深藏于腹腔内部，起病隐匿，早期症状不典型。临床上，胰腺癌的早期发现率仅为5~7%，是所有癌症中最低的一种。根据2025CSCO胰腺癌诊疗指南，超过80%的胰腺癌患者在确诊时已处于局部晚期或转移性阶段，错过了最佳的手术时机。晚期胰腺癌患者选择双药或三药的方案进行治疗，国内外均推荐首选吉西他滨联合白蛋白结合型紫杉醇方案，但目前一线标准疗法的ORR约23%-43%，中位OS仅8-11个月，仍存在巨大未满足的临床需求。近年来，基因学分子学检测技术的进步在胰腺癌发病机制、分子分型和药效等方面的研究中发挥了重要作用。基于生物学标志物的靶向治疗、免疫治疗在胰腺癌临床应用初现曙光。然而，晚期胰腺癌可干预靶点比较局限。例如，2017年美国批准了曲美替尼联合达拉非尼用于BRAF V600E突变阳性胰腺癌的治疗，但BRAF V600E在胰腺癌的突变率仅2.2%，患者人数较少。而BRCA1/2、NTRK融合的胰腺癌突变率则更低，分别为1.3%和0.3%。尽管目前已获批上市的靶点在胰腺癌中突变率有限，但一批潜力靶点正陆续崭露头角，包括RAS、Claudin18.2、TF等。（二）RAS：冉冉升起的潜力靶点 ‌RAS家族‌是一类关键的信号转导蛋白，属于小GTP酶超家族，在细胞增殖、分化和存活等过程中发挥核心“分子开关”作用。RAS家族包括三个高度同源的成员，分别是KRAS、NRAS和HRAS，其中KRAS占比最高，约占所有RAS突变的85%。在胰腺癌中，KRAS突变率高达90%，因此成为胰腺癌重要的治疗靶点。尽管目前已有KRAS G12C抑制剂用于胰腺癌的治疗，但由于KRAS G12C突变仅发生于大约1%~2%的胰腺癌中，因此能从该靶向治疗中受益的患者数量十分有限。而KRAS G12D在胰腺癌中的突变率高达30%-50%，在中国人群中发生率更高，因此成为胰腺癌靶向治疗领域亟待攻克的核心靶点。目前，最值得关注的KRAS靶向药物包括RMC-6236（RAS抑制剂）和RMC-9805（KRAS G12D抑制剂），均来自Revolution Medicines。（1）RMC-6236（Daraxonrasib）是一种在研的口服RAS（ON）多选择性非共价抑制剂，可通过抑制野生型和突变型RAS（ON）蛋白与其下游效应分子的相互作用，从而抑制RAS信号通路。RMC-6236目前处于临床Ⅲ期，2026年4月，Revolution Medicines公布了RMC-6236用于2L胰腺癌的Ⅲ期RASolute302试验结果，与标准化疗相比，每日口服一次Daraxonrasib，将中位总生存期由6.7个月提升至13.2个月，死亡风险降低60%。图：RMC-6236用于2L治疗胰腺癌的Ⅲ期数据数据来源：Revolution Medicines宣传资料除了2L治疗胰腺癌外，RMC-6236在1L胰腺癌适应症展现出了更有价值的治疗潜力。RMC-6236单药1L治疗胰腺癌的ORR达47%，6个月PFS率为71%，6个月OS率为83%。RMC-6236联合吉西他滨和白蛋白紫杉醇（GnP）1L治疗胰腺癌的ORR达58%，6个月PFS率为84%，6个月OS率为90%。图：RMC-6236用于1L治疗胰腺癌的临床数据数据来源：Revolution Medicines宣传资料（2）RMC-9805（Zoldonrasib）是一种在研的口服KRAS G12D选择性抑制剂，RMC-9805通过共价结合的方式锁定KRAS G12D蛋白的G12位点，阻断下游信号转导，抑制肿瘤细胞的增殖和存活信号通路（如MAPK/ERK通路）。 RMC-9805治疗胰腺癌的Ⅰ/Ⅰb期RMC-9805-001临床研究，纳入40名KRAS G12D突变、且既往接受过标准治疗的胰腺癌患者。结果显示，客观缓解率（ORR）达到30%（n = 12）。疾病控制率（DCR）达80%。图：RMC-9805 Ⅰ/Ⅰb研究结果数据来源：Revolution Medicines宣传资料（三）Claudin 18.2：胃癌和胰腺癌潜力靶点 Claudin是人体正常组织中紧密连接最重要的一种蛋白质，具有4个跨膜结构域，参与集体生理过程如细胞旁通透性和电导的调节，共同构成了细胞旁屏障。Claudin 18.2在正常组织中的表达水平较低，但在胃癌、胰腺癌、食管癌和肺癌等多种实体肿瘤中，尤其是胃癌（约60%至80%的病例）和胰腺癌（约50%的病例）中，Claudin 18.2呈现出高表达或过表达现象。鉴于Claudin18.2与胰腺癌关系密切，多个企业正在就Claudin18.2 治疗胰腺癌展开研究。（1）IBI343（Claudin18.2 ADC）和IBI389（CLDN18.2/CD3）是信达生物旗下两款靶向Claudin 18.2的产品，其中IBI343已授权武田。针对IBI343，在2025ASCO上，44名先前中位接受过2线治疗的CLDN18.2阳性的胰腺癌患者接受6mg/kg IBI343治疗，41.4%患者出现了3级或更高级别的TRAEs，在接受6mg/kg且CLDN18.2表达≥60%的44名可评估的PDAC患者中，ORR为22.7%，mPFS为5.4m，mOS为9.1m。图：IBI343 治疗胰腺癌Ⅰ期研究结果数据来源：2025 ASCO 针对IBI389，在2024年ASCO上，72名先前接受过1线治疗的CLDN18.2阳性的胰腺癌患者接受600ug/kg IBI389治疗，其中55.6%的患者先前接受过2线治疗，69.4%患者出现了3级或以上的TRAEs。在45名可评估疗效的患者中，针对CLDN 18.2表达≥10%的27名患者，ORR达29.6%，DCR达70.4%；针对CLDN 18.2表达≥40%的18名患者，ORR达38.9%，DCR为66.7%；。图：IBI389 治疗胰腺癌Ⅰ期研究结果数据来源：2024 ASCO （2）康诺亚/乐普生物旗下的CMG901 是一种 Claudin 18.2 靶向抗体偶联药物，由一个以 Claudin 18.2 为靶点的人源化单克隆抗体(CM311)、一个可裂解连接符和一种有效的细胞毒性载荷（MMAE，一种微管蛋白聚合抑制剂）组成，目前处于临床Ⅲ期。 CMG901目前正在开发的适应症包括胃癌和胰腺癌。2023年，康诺亚/乐普生物将CMG901授权阿斯利康，获得6300万美元的首付款和最高11.25亿美元的里程碑费用。2026年3月，康诺亚/乐普生物收到阿斯利康支付的4500万美元里程碑付款，触发的条件为CMG901启动一项联合卡培他滨联合或不联合Rilvegostomig一线治疗Claudin18.2阳性、HER2阴性的晚期/转移性胃癌、胃食管结合部癌或食管腺癌的多中心、随机对照、III期临床研究（CLARITY-Gastric 02），并完成了首例受试者给药。（三）TF：MRG004A已进入临床Ⅲ期组织因子（TF）是止血所必需的跨膜糖蛋白，随着肿瘤分子分型研究的不断深入，研究发现组织因子（TF）在多种癌症中的表达显著上升，特别是在胰腺癌中，且与不良预后和转移紧密相关。 MRG004A是乐普生物旗下一款TF ADC 药物，通过Glyco Connect™ 定点偶联及Hydra Space™极性间隔技术连接TF靶向单抗与高效抗微管剂 MMAE。2025年8月，MRG004A启动III期临床。在2025ESMO上，乐普生物披露了MRG004A治疗胰腺癌的Ⅰ期数据，39名先前接受过1线治疗的胰腺癌患者接受MRG004A的治疗，3级及以上TRAE为38.5%。疗效方面，针对10名先前接受过1线治疗的患者，ORR为40%，mPFS为5.8m，mOS为13.2m；针对27名先前接受过2线治疗的患者，ORR为18.5%，mPFS为2.7m，mOS为5.8m。图：MRG004A治疗胰腺癌Ⅰ期疗效数据数据来源：2025ESMO （四）小结胰腺癌被称为癌症之王，源于其恶性程度高，起病隐匿，且早期症状不典型，临床存在迫切的治疗需求。RAS、Claudin18.2和TF 等靶点有望突围癌症之王，就RAS靶点，RMC-6236已在三期临床研究中证实其OS的显著性，相较化疗死亡风险降低60%；Claudin 18.2药物布局企业较多，其中信达生物的IBI343和康诺亚/乐普生物的CMG901均成功授权，期待未来武田和阿斯利康海外的持续突破；乐普生物的MRG004A是TF ADC领域的佼佼者，2L治疗胰腺癌mOS高达13.2m，已于2025年进入临床Ⅲ期。期待这些重磅药物未来攻克癌症之王。立即扫码加入药事纵横交流群

2026-05-04

·PRNewswire

Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

HOLON, Israel, May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its first quarter 2026 financial results on Monday, May 18, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link. Following the live webcast, a replay will be available on the Company's website. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody, have been evaluated for the treatment of solid tumors as monotherapy and in combinations of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Currently, the only clinical trial we sponsor and are conducting is a blinded randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between us and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that we sponsor and are conducting. In addition, Compugen's has an early-stage immuno-oncology pipeline consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company Contact: Investor relations Email: [email protected] Tel: +1 (628) 241-0071 SOURCE Compugen Ltd. 21% more press release views with Request a Demo

引进/卖出临床1期免疫疗法临床2期财报

100 项与 Rilvegostomig 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
食管腺癌	临床3期	美国	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	中国	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	日本	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	澳大利亚	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	奥地利	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	比利时	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	巴西	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	加拿大	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	法国	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	德国	AstraZeneca PLC	2026-02-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05414032 (MERIDIAN, AACR2026)	临床2期	晚期头颈部鳞状细胞癌 human papillomavirus (HPV)	46	Rilvegostomig 750mg IV q3w x 6	簾憲獵憲積鹽積壓鬱網(窪窪鏇製範鹹夢淵糧鹹) = The pt on Rv achieved ctDNA clearance at Part D weeks 2 and 10 and remains recurrence-free with undetectable ctDNA 12 months post-Rv. 鏇餘艱鑰醖鬱繭鬱蓋範 (構鹽鬱憲選艱觸餘餘鑰 ) 更多	积极	2026-04-20
NCT06989112 (DESTINY-Endometrial01, ESGO2026)	临床3期	复发性子宫内膜癌一线 HER2-expressing \| mismatch repair-proficient (pMMR)	600	trastuzumab deruxtecan + rilvegostomig	窪夢廠醖餘襯製觸襯築(醖鑰觸築築網簾醖淵蓋) = 醖憲選艱繭遞糧齋餘襯鬱築廠顧壓憲餘憲憲繭 (鏇齋築膚窪廠壓選醖顧, 24.9 ~ NR) 更多	积极	2026-02-28
				trastuzumab deruxtecan + pembrolizumab	壓蓋糧憲壓觸顧顧膚蓋(願鬱願蓋獵醖憲製鹽獵) = 齋廠積衊夢構簾廠網鏇艱顧網鬱窪蓋鹽淵獵網 (鑰鹽壓繭壓鹽憲選壓觸, 8.3 ~ 16.5) 更多
NCT06764875 (ARTEMIDE-Gastric01, ASCO_GI2026)	临床3期	转移性 HER2 阳性胃食管结合部癌一线 HER2-positive \| PD-L1 CPS ≥1	840	rilvegostomig + T-DXd + investigator’s choice of capecitabine or 5-fluorouracil (5-FU)	積選願遞網範淵憲範觸(鹹遞積鏇鬱膚艱鹽餘築) = 艱遞襯製範窪淵餘齋繭積淵襯製餘範鹽繭鏇齋 (艱觸範糧鑰網壓糧窪簾, 24.9 ~ NR)	积极	2026-01-08
				rilvegostomig + trastuzumab + investigator’s choice of FP or CAPOX	觸積餘襯繭網顧遞鏇淵(積顧鬱鏇構鹹鏇鏇選觸) = 鬱憲鑰顧製鹹蓋構窪構鏇鏇艱選鏇顧繭顧淵淵 (窪鹹膚獵鹽繭壓積鑰簾, 17.0 ~ NR) 更多
NCT06921785 (ARTEMIDE-HCC01, ESMO_ASIA2025)	临床3期	不可切除的肝细胞癌一线	1,220	Rilvegostomig + Bevacizumab + Tremelimumab	製窪餘獵夢簾餘鑰獵膚(夢獵網構鏇廠遞獵廠淵) = 醖觸顧齋餘艱憲簾壓餘簾顧製蓋構糧膚鏇壓醖 (醖遞襯築壓遞鏇繭鹽壓, 17 ~ 32) 更多	积极	2025-12-05
				Tremelimumab + Rilvegostomig + Bevacizumab	製窪餘獵夢簾餘鑰獵膚(夢獵網構鏇廠遞獵廠淵) = 觸膚艱鬱積醖選襯積鏇簾顧製蓋構糧膚鏇壓醖 (醖遞襯築壓遞鏇繭鹽壓, 17 ~ 32) 更多
NCT06868277 (ARTEMIDE-Lung04, ESMO2025)	临床3期	转移性非小细胞肺癌一线 PD-L1 expression ≥50%	830	Rilvegostomig	繭鏇築淵範壓構製蓋獵(積獵衊鹽壓齋繭淵鹹獵) = 憲廠獵餘鹹憲構餘獵糧遞淵範廠願遞齋鏇憲獵 (範願憲鬱艱餘鏇網觸齋 ) 更多	积极	2025-10-17
				Pembrolizumab	繭鏇築淵範壓構製蓋獵(積獵衊鹽壓齋繭淵鹹獵) = 遞醖網觸築廠製範鹽鏇遞淵範廠願遞齋鏇憲獵 (範願憲鬱艱餘鏇網觸齋 ) 更多
NCT05775159 (GEMINI-Hepatobiliary substudy 2 Cohort A, ASCO2025)	临床2期	晚期胆道癌一线	-	Rilve plus Gemcitabine and Cisplatin	範餘憲夢鹽積範壓鹹夢(醖顧壓膚鑰繭構餘廠醖) = 餘鹽衊淵餘淵繭膚壓醖憲餘範餘鹽鏇鏇廠艱築 (簾積鹽選廠蓋顧憲艱蓋 ) 更多	积极	2025-05-30
NCT05702229 (GEMINI-Gastric, ESMO2024) 人工标引	临床2期	HER2阴性胃癌一线 HER2-negative	40	Rilvegostomig 750 mg Q3W IV + XELOX (oxaliplatin + capecitabine)	願繭糧鏇觸淵醖繭顧膚(遞餘淵窪選夢選醖積鏇) = 艱鹽簾淵顧網鬱鏇構蓋夢範選衊鬱醖獵糧築網 (範觸築鏇艱鹹願蓋遞鏇, 50.9 ~ 81.4) 更多	积极	2024-09-16
NCT04995523 (ARTEMIDE-01, WCLC2024) 人工标引	临床1/2期	转移性非小细胞肺癌二线 \| 一线 PD-L1	96	Rilvegostomig 750 mg (PD-L1 TPS 1-49%)	廠鹹鏇顧選鹽鑰鏇觸艱(窪餘網簾廠壓積廠憲憲) = 範獵窪艱網壓範夢繭築鹽壓壓夢築壓蓋選淵獵 (鏇選範鹽餘簾淵範憲簾 ) 更多	积极	2024-09-09
				Rilvegostomig 750 mg	廠鹹鏇顧選鹽鑰鏇觸艱(窪餘網簾廠壓積廠憲憲) = 醖簾觸蓋壓積夢壓遞鹹鹽壓壓夢築壓蓋選淵獵 (鏇選範鹽餘簾淵範憲簾 ) 更多
NCT04995523 (ARTEMIDE-01, ESMO 12023 \| ESMO 22023) 人工标引	临床1/2期	非小细胞肺癌二线	83	rilvegostomig	夢鏇築艱鏇鬱廠膚願簾(獵簾遞餘網製蓋蓋艱獵) = 齋顧鏇窪構製壓鹹鏇蓋廠範繭鏇簾窪簾網夢夢 (築積積簾憲膚憲鏇鏇糧, 1.3 ~ 11.9) 更多	积极	2023-10-23
NCT04995523 (ARTEMIDE-01, ASCO 12023 \| ASCO 22023) 人工标引	临床1/2期	转移性非小细胞肺癌	80	AZD2936 (overall)	鹽選艱衊鹹窪築鏇膚醖(憲壓鏇網製鬱選遞夢淵) = 選鹹鹽糧壓願遞繭鑰夢構廠鏇製憲淵壓積艱構 (醖鬱範鏇鏇選製願繭蓋 ) 更多	积极	2023-05-26